{"id":"cmab807-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of CMAB807 has not been widely disclosed in public literature, Shanghai Biomabs' pipeline suggests it is likely a checkpoint inhibitor or targeted immunotherapy. The drug is designed to modulate immune function through antibody-mediated mechanisms, potentially blocking inhibitory signals on T cells or targeting tumor-associated antigens to promote anti-tumor activity.","oneSentence":"CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:29.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT04591275","phase":"PHASE3","title":"Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2021-03-31","conditions":"Postmenopausal Osteoporosis","enrollment":278},{"nctId":"NCT06361355","phase":"PHASE1","title":"Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-11-02","conditions":"Healthy Volunteers","enrollment":128},{"nctId":"NCT03925051","phase":"PHASE1","title":"Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2019-07-01","conditions":"Postmenopausal Osteoporosis","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Denosumab Injection"],"phase":"phase_3","status":"active","brandName":"CMAB807 Injection","genericName":"CMAB807 Injection","companyName":"Shanghai Biomabs Pharmaceutical Co., Ltd.","companyId":"shanghai-biomabs-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses. Used for Solid tumors (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}